Drug
Anavex2 73
Anavex2 73: highest development phase Phase 3, developed by Anavex Life Sciences. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Anavex Life Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| ANAVEX2-73 NCT03941444 | Phase 3 | Rett Syndrome |
| ANAVEX2-73 NCT04314934 | Phase 2/3 | Alzheimer Disease |
| ANAVEX2-73 NCT04575259 | Phase 2 | Parkinson Disease Dementia |
| ANAVEX2-73 Oral NCT02244541 | Phase 2 | Alzheimer's Disease |
| ANAVEX2-73 NCT02756858 | Phase 2 | Alzheimer's Disease |
| ANAVEX2-73 NCT03758924 | Phase 2 | Rett Syndrome |
Latest
No recent events.
Follow Anavex2 73 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.